Antiangiogenic therapy for normalization of tumor vasculature and microenvironment

Rakesh K. Jain; Dan G. Duda

doi:10.1007/978-3-540-33177-3_33

Antiangiogenic therapy for normalization of tumor vasculature and microenvironment

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3-4 years. As a result, there are currently three direct blockers of the VEGF pathway approved for use in cancer, and two others for age-related wet macular degeneration. Other agents that block the VEGF pathway are currently in advanced stages of clinical development and have shown promising results. With these exciting developments come critical questions regarding the use of these new molecularly targeted agents, alone or in combination with standard cytotoxic or targeted agents.

Original language	English (US)
Title of host publication	Tumor Angiogenesis
Subtitle of host publication	Basic Mechanisms and Cancer Therapy
Publisher	Springer Berlin Heidelberg
Pages	577-592
Number of pages	16
ISBN (Print)	9783540331766
DOIs	https://doi.org/10.1007/978-3-540-33177-3_33
State	Published - 2008

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-540-33177-3_33

Cite this

@inbook{c17a1032b66b47109dbbc7a530614a5f,

title = "Antiangiogenic therapy for normalization of tumor vasculature and microenvironment",

abstract = "Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3-4 years. As a result, there are currently three direct blockers of the VEGF pathway approved for use in cancer, and two others for age-related wet macular degeneration. Other agents that block the VEGF pathway are currently in advanced stages of clinical development and have shown promising results. With these exciting developments come critical questions regarding the use of these new molecularly targeted agents, alone or in combination with standard cytotoxic or targeted agents.",

author = "Jain, \{Rakesh K.\} and Duda, \{Dan G.\}",

year = "2008",

doi = "10.1007/978-3-540-33177-3\_33",

language = "English (US)",

isbn = "9783540331766",

pages = "577--592",

booktitle = "Tumor Angiogenesis",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Antiangiogenic therapy for normalization of tumor vasculature and microenvironment

AU - Jain, Rakesh K.

AU - Duda, Dan G.

PY - 2008

Y1 - 2008

N2 - Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3-4 years. As a result, there are currently three direct blockers of the VEGF pathway approved for use in cancer, and two others for age-related wet macular degeneration. Other agents that block the VEGF pathway are currently in advanced stages of clinical development and have shown promising results. With these exciting developments come critical questions regarding the use of these new molecularly targeted agents, alone or in combination with standard cytotoxic or targeted agents.

AB - Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3-4 years. As a result, there are currently three direct blockers of the VEGF pathway approved for use in cancer, and two others for age-related wet macular degeneration. Other agents that block the VEGF pathway are currently in advanced stages of clinical development and have shown promising results. With these exciting developments come critical questions regarding the use of these new molecularly targeted agents, alone or in combination with standard cytotoxic or targeted agents.

UR - https://www.scopus.com/pages/publications/84892109451

UR - https://www.scopus.com/inward/citedby.url?scp=84892109451&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-33177-3_33

DO - 10.1007/978-3-540-33177-3_33

M3 - Chapter

AN - SCOPUS:84892109451

SN - 9783540331766

SP - 577

EP - 592

BT - Tumor Angiogenesis

PB - Springer Berlin Heidelberg

ER -

Antiangiogenic therapy for normalization of tumor vasculature and microenvironment

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this